ArticleScientific reports2018
Broad-spectrum neutralization of avian influenza viruses by sialylated human milk oligosaccharides: in vivo assessment of 3'-sialyllactose against H9N2 in chickens.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Human Milk Oligosaccharides: Shaping the Anti-Infective Status in Infancy.Microorganisms · 2026Review
- A sialic acid-binding protein in Toxoplasma gondii contains a conserved globular domain in apicomplexan parasites.Parasites & vectors · 2025Article
- Human milk oligosaccharide secretion dynamics during breastfeeding and its antimicrobial role: A systematic review.World journal of clinical pediatrics · 2025Article
- In Vivo Evidence on the Emerging Potential of Non-Digestible Oligosaccharides as Therapeutic Agents in Bacterial and Viral Infections.Nutrients · 2025Review
- Sialic acids in infection and their potential use in detection and protection against pathogens.RSC chemical biology · 2024Review
- Targeting host-virus interactions: in silico analysis of the binding of human milk oligosaccharides to viral proteins involved in respiratory infections.Scientific reports · 2024Article
- Enhancing immune regulationFrontiers in immunology · 2024Article
- Biological effects of combinations of structurally diverse human milk oligosaccharides.Frontiers in pediatrics · 2024Review
- Viruses and Human Milk: Transmission or Protection?Advances in nutrition (Bethesda, Md.) · 2023Review
- Human Milk Oligosaccharides: Potential Applications in COVID-19.Biomedicines · 2022Review
- Role of milk glycome in prevention, treatment, and recovery of COVID-19.Frontiers in nutrition · 2022Review
- Ingestion, Immunity, and Infection: Nutrition and Viral Respiratory Tract Infections.Frontiers in immunology · 2022Review
- Role of sialylated glycans on bovine lactoferrin against influenza virus.Glycoconjugate journal · 2021Article
- Studies and Application of Sialylated Milk Components on Regulating Neonatal Gut Microbiota and Health.Frontiers in nutrition · 2021Review
- Review
- Anti-Infective, Anti-Inflammatory, and Immunomodulatory Properties of Breast Milk Factors for the Protection of Infants in the Pandemic From COVID-19.Frontiers in public health · 2020Article
- Computational search for potential COVID-19 drugs from FDAapproved drugs and small molecules of natural origin identifies several anti-virals and plant products.Journal of biosciences · 2020Article
- Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies.Nature communications · 2019Article
- Diversity of Human Milk Oligosaccharides and Effects on Early Life Immune Development.Frontiers in pediatrics · 2018Review
- The Prebiotic and Probiotic Properties of Human Milk: Implications for Infant Immune Development and Pediatric Asthma.Frontiers in pediatrics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two sialylated human milk oligosaccharides (SHMOs) 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL) were accessed for their possible antiviral activity against six different subtypes of thirteen avian influenza (AI) viruses in vitro. 3'-SL exhibited promising antiviral activity against almost all subtypes of tested AI viruses in hemagglutination inhibition assay, whereas 6'-SL showed activity against few selected H1N1, H1N2, and H3N2 subtype strains. 3'-SL has minimum inhibitory concentration values of 15.62 mM or less in more than half of the viruses examined. 3'-SL also showed effective inactivation of H9N2 Korea isolate (A/Chicken/Korea/MS96/1996) at 12.5 mM concentration in Madin Darby Canine Kidney (MDCK) cell line. Thus, 3'-SL was further studied for in vivo study against H9N2 virus in pathogen free chicken experiment models. In vivo study exhibited improved clinical symptoms on H9N2 infected chickens when treated with 3'-SL. Moreover, treating chickens with 3'-SL resulted in complete elimination of H9N2 viruses within 24 h of virus infection (0.8 HAU of H9N2). Indirect ELISA assay confirmed complete wash-out of H9N2 viruses from the colon after neutralization by 3'-SL without entering the blood stream. These in vivo results open up possible applications of 3'-SL for the prevention of AI virus infections in birds by a simple cleansing mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.